Biotech Business - June 8, 2022
Elicera Therapeutics receives 2.5 million EUR in EU funding
Elicera Therapeutics has been awarded funding from the European Innovation Council (EIC) Accelerator Programme. The grant is sufficient to fully fund Elicera’s planned clinical phase I/II-study evaluating its CAR T-cell therapy ELC-301 in the treatment of B-cell lymphoma, the company states. “This grant has major positive implications for the development of our CAR T-cell therapy, […]
Biotech Business - June 2, 2022
Asgard Therapeutics granted US patent
Asgard Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Asgard’s foundational patent related to the method of reprogramming cells towards the dendritic cell fate. The patent provides protection and market exclusivity of products based in the cell reprogramming method until 2038, such as Asgard’s innovative cancer immunotherapies, describes the […]
Biotech Business - June 1, 2022
Spago Nanomedical carries out a rights issue of up to 61.8 million SEK
The Board of Directors of Spago Nanomedical has resolved to carry out a rights issue with preferential rights for existing shareholders of up to 61.8 MSEK before issue costs. Four (4) shares in Spago Nanomedical entitle for subscription of five (5) new shares in the Rights Issue at a subscription price of SEK 1.20 per […]
Biotech Business - May 30, 2022
Xbrane withdraws BLA for Lucentis
Xbrane Biopharma has withdrawn the BLA (Biologics License Application) for its investigational biosimilar candidate to Lucentis after receiving feedback from the FDA that complementary information is required for the FDA to take the decision to accept the BLA and initiate the review. Xbrane will receive more information about the requested complementary information from the FDA […]
Biotech Business - May 23, 2022
Calliditas receives positive CHMP opinion
Calliditas Therapeutics has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional marketing authorisation for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine […]
Biotech Business - May 18, 2022
Immunovia Inc achieves Clinical Laboratory Licensure
The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia, Clinical Laboratory licensure. The licensure allows physicians in Rhode Island to order the IMMray PanCan-d test for their patients. “Receiving licensure in Rhode Island now allows us to offer IMMray PanCan-d in 46 states. We expect additional state licensures to […]
